nach oben

Erschienen in:

17.05.2019 | Original Article

Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice

verfasst von: Ya-Lan Dong, Xue-Yun Duan, Yu-Jin Liu, Heng Fan, Meng Xu, Qian-Yun Chen, Zhen Nan, Hui Wu, Shuang-Jiao Deng

Erschienen in: Inflammation | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Autotaxin-lysophosphatidic acid (ATX-LPA) axis is closely associated with several inflammation-related diseases. In the colonic mucosa of patients with chronic ulcerative colitis (UC), the expression of ATX and the percentage of Th17 cells are found to increase. However, it is unclear whether ATX-LPA axis affects the differentiation of Th17 cells in chronic UC. To investigate whether ATX-LPA axis contributes to Th17 cell differentiation, a mouse model of chronic UC was established by drinking water with DSS at intervals. ATX inhibitor was used as an intervention. The disease active index (DAI), colonic weight to length ratio, colon length, colon histopathology, and MAdCAM-1 were observed. Additionally, the expression of ATX, LPA receptor, CD34, IL-17A, IL-21, IL-6, ROR-γt, STAT3 in colonic tissue, and the percentage of Th17 cells in spleens and mesenteric lymph nodes (MLNs) were measured using different methods. ATX blockade was able to relieve symptoms and inflammatory response of DSS-induced chronic colitis. The DAI and colonic weight to length ratio were apparently decreased, while the colon length was increased. The pathological damage and colitis severity were lighter in the inhibitor group than that in the DSS group. Inhibiting ATX reduced the expression of ATX, LPA receptor, and CD34 and also decreased the percentages of Th17 cells in spleens and MLNs and the expressions of IL-17A and IL-21, as well as the factors in Th17 cell signaling pathway including IL-6, ROR-γt, and STAT3 in colonic tissue. ATX-LPA axis blockade could alleviate inflammation by suppressing Th17 cell differentiation in chronic UC.

Ungaro, R., S. Mehandru, P.B. Allen, L. Peyrin-Biroulet, and J.F. Colombel. 2017. Ulcerative colitis. Lancet 389: 1756–1770.CrossRefPubMed

Ng, S.C., H.Y. Shi, N. Hamidi, F.E. Underwood, W. Tang, E.I. Benchimol, R. Panaccione, S. Ghosh, J.C.Y. Wu, F.K.L. Chan, J.J.Y. Sung, and G.G. Kaplan. 2018. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390: 2769–2778.CrossRef

Bopanna, S., A.N. Ananthakrishnan, S. Kedia, V. Yajnik, and V. Ahuja. 2017. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2: 269–276.CrossRef

Cleynen, I., G. Boucher, L. Jostins, L.P. Schumm, S. Zeissig, T. Ahmad, V. Andersen, J.M. Andrews, V. Annese, S. Brand, S.R. Brant, J.H. Cho, M.J. Daly, M. Dubinsky, R.H. Duerr, L.R. Ferguson, A. Franke, R.B. Gearry, P. Goyette, H. Hakonarson, J. Halfvarson, J.R. Hov, H. Huang, N.A. Kennedy, L. Kupcinskas, I.C. Lawrance, J.C. Lee, J. Satsangi, S. Schreiber, E. Théâtre, A. van der Meulen-de Jong, R.K. Weersma, D.C. Wilson, International Inflammatory Bowel Disease Genetics Consortium, M. Parkes, S. Vermeire, J.D. Rioux, J. Mansfield, M.S. Silverberg, G. Radford-Smith, D. McGovern, J.C. Barrett, and C.W. Lees. 2016. Inherited determinants of Crohn’s disease and ulcerative colitis phenotypes: a genetic association study. Lancet 387: 156–167.CrossRefPubMedPubMedCentral

Hibi, T., and H. Ogata. 2006. Novel pathophysiological concepts of inflammatory bowel disease. Journal of Gastroenterology 41: 10–16.CrossRefPubMed

Xu, M., D. Zuo, X. Liu, H. Fan, Q. Chen, S. Deng, Z. Shou, Q. Tang, J. Yang, Z. Nan, H. Wu, Y. Dong, and Y. Liu. 2017. MiR-155 contributes to Th17 cells differentiation in dextran sulfate sodium (DSS)-induced colitis mice via Jarid2. Biochemical and Biophysical Research Communications 488: 6–14.CrossRefPubMed

Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65–70.CrossRefPubMedPubMedCentral

Harrington, L.E., P.R. Mangan, and C.T. Weaver. 2006. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Current Opinion in Immunology 18: 349–356.CrossRefPubMed

Kobayashi, T., S. Okamoto, T. Hisamatsu, N. Kamada, H. Chinen, R. Saito, M.T. Kitazume, A. Nakazawa, A. Sugita, K. Koganei, K. Isobe, and T. Hibi. 2008. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut 57: 1682–1689.CrossRefPubMed

10.

Hirota, K., M. Hashimoto, Y. Ito, M. Matsuura, H. Ito, M. Tanaka, H. Watanabe, G. Kondoh, A. Tanaka, K. Yasuda, M. Kopf, A.J. Potocnik, B. Stockinger, N. Sakaguchi, and S. Sakaguchi. 2018. Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis. Immunity 48: 1220–1232.e5.CrossRefPubMedPubMedCentral

11.

Machino-Ohtsuka, T., K. Tajiri, T. Kimura, S. Sakai, A. Sato, T. Yoshida, et al. 2014. Tenascin-C aggravates autoimmune myocarditis via dendritic cell activation and Th17 cell differentiation. Journal of the American Heart Association 3: e001052.CrossRefPubMedPubMedCentral

12.

Coskun, M., M. Salem, J. Pedersen, and O.H. Nielsen. 2013. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacological Research 76: 1–8.CrossRefPubMed

13.

Withers, D.R., M.R. Hepworth, X. Wang, E.C. Mackley, E.E. Halford, E.E. Dutton, C.L. Marriott, V. Brucklacher-Waldert, M. Veldhoen, J. Kelsen, R.N. Baldassano, and G.F. Sonnenberg. 2016. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nature Medicine 22: 319–323.CrossRefPubMedPubMedCentral

14.

Guo, D., Y. Chen, S. Wang, L. Yu, Y. Shen, H. Zhong, et al. Exosomes from heat-stressed tumour cells inhibit tumour growth by converting regulatory T cells to Th17 cells via IL-6. Immunology 2017.

15.

Li, X., A.R. Cannon, A.M. Hammer, N.L. Morris, and M.A. Choudhry. 2017. IL-23 restoration of Th17 effector function is independent of IL-6 and TGF-beta in a mouse model of alcohol and burn injury. Journal of Leukocyte Biology 102: 915–923.CrossRefPubMedPubMedCentral

16.

Ghoreschi, K., A. Laurence, X.P. Yang, C.M. Tato, M.J. McGeachy, J.E. Konkel, et al. 2010. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467: 967–971.CrossRefPubMedPubMedCentral

17.

Kano, K., N. Arima, M. Ohgami, and J. Aoki. 2008. LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Current Medicinal Chemistry 15: 2122–2131.CrossRefPubMed

18.

Umezu-Goto, M., Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G.B. Mills, K. Inoue, J. Aoki, and H. Arai. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of Cell Biology 158: 227–233.CrossRefPubMedPubMedCentral

19.

Gardell, S.E., A.E. Dubin, and J. Chun. 2006. Emerging medicinal roles for lysophospholipid signaling. Trends in Molecular Medicine 12: 65–75.CrossRefPubMed

20.

Chu, X., X. Wei, S. Lu, and P. He. 2015. Autotaxin-LPA receptor axis in the pathogenesis of lung diseases. International Journal of Clinical and Experimental Medicine 8: 17117–17122.PubMedPubMedCentral

21.

Zhang, Y., Y.C. Chen, M.F. Krummel, and S.D. Rosen. 2012. Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. Journal of Immunology 189: 3914–3924.CrossRef

22.

Mills, G.B., and W.H. Moolenaar. 2003. The emerging role of lysophosphatidic acid in cancer. Nature Reviews. Cancer 3: 582–591.CrossRefPubMed

23.

Tager, A.M. 2012. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. American Journal of Respiratory Cell and Molecular Biology 47: 563–565.CrossRefPubMedPubMedCentral

24.

Watanabe, N., H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, J. Aoki, K. Hama, S. Okudaira, M. Tanaka, T. Tomiya, M. Yanase, K. Tejima, T. Nishikawa, M. Arai, H. Arai, M. Omata, K. Fujiwara, and Y. Yatomi. 2007. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. Journal of Clinical Gastroenterology 41: 616–623.CrossRefPubMed

25.

Hozumi, H., R. Hokari, C. Kurihara, K. Narimatsu, H. Sato, S. Sato, T. Ueda, M. Higashiyama, Y. Okada, C. Watanabe, S. Komoto, K. Tomita, A. Kawaguchi, S. Nagao, and S. Miura. 2013. Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration. Laboratory Investigation 93: 508–519.CrossRefPubMed

26.

Wirtz, S., V. Popp, M. Kindermann, K. Gerlach, B. Weigmann, S. Fichtner-Feigl, and M.F. Neurath. 2017. Chemically induced mouse models of acute and chronic intestinal inflammation. Nature Protocols 12: 1295–1309.CrossRefPubMed

27.

Yang, J., X.X. Liu, H. Fan, Q. Tang, Z.X. Shou, D.M. Zuo, Z. Zou, M. Xu, Q.Y. Chen, Y. Peng, S.J. Deng, and Y.J. Liu. 2015. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation, oxidative stress and apoptosis. PLoS One 10: e0140551.CrossRefPubMedPubMedCentral

28.

Saunders, L.P., A. Ouellette, R. Bandle, W.C. Chang, H. Zhou, R.N. Misra, E.M. de la Cruz, and D.T. Braddock. 2008. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Molecular Cancer Therapeutics 7: 3352–3362.CrossRefPubMedPubMedCentral

29.

Totsuka, T., T. Kanai, Y. Nemoto, S. Makita, R. Okamoto, K. Tsuchiya, and M. Watanabe. 2007. IL-7 is essential for the development and the persistence of chronic colitis. Journal of Immunology 178: 4737–4748.CrossRef

30.

Zhang, L., Y. Zhang, W. Zhong, C. Di, X. Lin, and Z. Xia. 2014. Heme oxygenase-1 ameliorates dextran sulfate sodium-induced acute murine colitis by regulating Th17/Treg cell balance. The Journal of Biological Chemistry 289: 26847–26858.CrossRefPubMedPubMedCentral

31.

Vermeire, S., W.J. Sandborn, S. Danese, X. Hebuterne, B.A. Salzberg, M. Klopocka, et al. 2017. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 390: 135–144.CrossRefPubMed

32.

Fujimori, H., S. Miura, S. Koseki, R. Hokari, S. Komoto, Y. Hara, S. Hachimura, S. Kaminogawa, and H. Ishii. 2002. Intravital observation of adhesion of lamina propria lymphocytes to microvessels of small intestine in mice. Gastroenterology 122: 734–744.CrossRefPubMed

33.

Knowlden, S., and S.N. Georas. 2014. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. Journal of Immunology 192: 851–857.CrossRef

34.

Wei, L., A. Laurence, K.M. Elias, and J.J. O'Shea. 2007. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. The Journal of Biological Chemistry 282: 34605–34610.CrossRefPubMed

35.

Peloquin, J.M., G. Goel, E.J. Villablanca, and R.J. Xavier. 2016. Mechanisms of pediatric inflammatory bowel disease. Annual Review of Immunology 34: 31–64.CrossRefPubMed

36.

Low, D., D.D. Nguyen, and E. Mizoguchi. 2013. Animal models of ulcerative colitis and their application in drug research. Drug Design, Development and Therapy 7: 1341–1357.PubMedPubMedCentral

37.

Chen, Q., X. Duan, H. Fan, M. Xu, Q. Tang, L. Zhang, Z. Shou, X. Liu, D. Zuo, J. Yang, S. Deng, Y. Dong, H. Wu, Y. Liu, and Z. Nan. 2017. Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway. International Immunopharmacology 53: 149–157.CrossRefPubMed

38.

Liu, Y., Y. Dong, X. Zhu, H. Fan, M. Xu, Q. Chen, Z. Nan, H. Wu, S. Deng, X. Liu, D. Zuo, and J. Yang. 2018. MiR-155 inhibition ameliorates 2, 4, 6-Trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis in rat via influencing the differentiation of Th17 cells by Jarid2. International Immunopharmacology 64: 401–410.CrossRefPubMed

39.

Xu, A., K.K.M. Ahsanul, F. Chen, Z. Zhong, H.C. Chen, and Y. Song. 2016. Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression. Medical Oncology 33: 131.CrossRefPubMed

40.

Castelino, F.V., G. Bain, V.A. Pace, K.E. Black, L. George, C.K. Probst, L. Goulet, R. Lafyatis, and A.M. Tager. 2016. An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis & Rhematology 68: 2964–2974.CrossRef

41.

Orosa, B., S. Garcia, and C. Conde. 2015. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis. European Journal of Pharmacology 765: 228–233.CrossRefPubMed

42.

Lee, S.J., and C.C. Yun. 2010. Colorectal cancer cells - proliferation, survival and invasion by lysophosphatidic acid. The International Journal of Biochemistry & Cell Biology 42: 1907–1910.CrossRef

43.

Lee, S.C., Y. Fujiwara, J. Liu, J. Yue, Y. Shimizu, D.D. Norman, Y. Wang, R. Tsukahara, E. Szabo, R. Patil, S. Banerjee, D.D. Miller, L. Balazs, M.C. Ghosh, C.M. Waters, T. Oravecz, and G.J. Tigyi. 2015. Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis. Molecular Cancer Research 13: 174–185.CrossRefPubMed

44.

Savaskan, N.E., L. Rocha, M.R. Kotter, A. Baer, G. Lubec, L.A. van Meeteren, Y. Kishi, J. Aoki, W.H. Moolenaar, R. Nitsch, and A.U. Bräuer. 2007. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. Cellular and Molecular Life Sciences 64: 230–243.CrossRefPubMed

45.

Tager, A.M., P. LaCamera, B.S. Shea, G.S. Campanella, M. Selman, Z. Zhao, V. Polosukhin, J. Wain, B.A. Karimi-Shah, N.D. Kim, W.K. Hart, A. Pardo, T.S. Blackwell, Y. Xu, J. Chun, and A.D. Luster. 2008. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nature Medicine 14: 45–54.CrossRefPubMed

46.

Saunders, J.A., L.C. Rogers, C. Klomsiri, L.B. Poole, and L.W. Daniel. 2010. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radical Biology & Medicine 49: 2058–2067.CrossRef

47.

Saatian, B., Y. Zhao, D. He, S.N. Georas, T. Watkins, E.W. Spannhake, and V. Natarajan. 2006. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. The Biochemical Journal 393: 657–668.CrossRefPubMedPubMedCentral

48.

Chou, C.H., L.H. Wei, M.L. Kuo, Y.J. Huang, K.P. Lai, C.A. Chen, and C.Y. Hsieh. 2005. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 26: 45–52.CrossRefPubMed

49.

Wu, X., and H. Wang. 2013. The important role of lysophosphatidic acid (LPA) induced interleukin-6 and -8 syntheses by human osteoblasts in skeletal biology. Bone 55: 268.CrossRefPubMed

50.

Hwang, Y.S., S.K. Lee, K.K. Park, and W.Y. Chung. 2012. Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption. Oral Oncology 48: 40–48.CrossRefPubMed

51.

Kime, C., M. Sakaki-Yumoto, L. Goodrich, Y. Hayashi, S. Sami, R. Derynck, M. Asahi, B. Panning, S. Yamanaka, and K. Tomoda. 2016. Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program. Proceedings of the National Academy of Sciences of the United States of America 113: 12478–12483.CrossRefPubMedPubMedCentral

52.

Seo, J.H., K.J. Jeong, W.J. Oh, H.J. Sul, J.S. Sohn, Y.K. Kim, D.Y. Cho, J.K. Kang, C.G. Park, and H.Y. Lee. 2010. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Letters 288: 50–56.CrossRefPubMed

53.

Yang, X.O., A.D. Panopoulos, R. Nurieva, S.H. Chang, D. Wang, S.S. Watowich, and C. Dong. 2007. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. The Journal of Biological Chemistry 282: 9358–9363.CrossRefPubMed

54.

Yang, Y., R.C. Winger, P.W. Lee, P.K. Nuro-Gyina, A. Minc, M. Larson, Y. Liu, W. Pei, E. Rieser, M.K. Racke, and A.E. Lovett-Racke. 2015. Impact of suppressing retinoic acid-related orphan receptor gamma t (ROR)gamma t in ameliorating central nervous system autoimmunity. Clinical and Experimental Immunology 179: 108–118.CrossRefPubMed

55.

Tokumura, A. 2002. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochimica et Biophysica Acta 1582: 18–25.CrossRefPubMed

Titel: Autotaxin-Lysophosphatidic Acid Axis Blockade Improves Inflammation by Regulating Th17 Cell Differentiation in DSS-Induced Chronic Colitis Mice
verfasst von: Ya-Lan Dong
Xue-Yun Duan
Yu-Jin Liu
Heng Fan
Meng Xu
Qian-Yun Chen
Zhen Nan
Hui Wu
Shuang-Jiao Deng
Publikationsdatum: 17.05.2019
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 5/2019
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-019-01015-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Protective Effects of Tyrosol Against DSS-Induced Ulcerative Colitis in Rats

Fraxin Alleviates LPS-Induced ARDS by Downregulating Inflammatory Responses and Oxidative Damages and Reducing Pulmonary Vascular Permeability

Electroacupuncture Pretreatment Elicits Neuroprotection Against Cerebral Ischemia-Reperfusion Injury in Rats Associated with Transient Receptor Potential Vanilloid 1-Mediated Anti-Oxidant Stress and Anti-Inflammation

MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer

Pseudoginsenoside-F11 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Neutrophil Infiltration and Accelerating Neutrophil Clearance